Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Respiratory Research

Fig. 1

From: ZDHXB-101 (3′,5-Diallyl-2, 4′-dihydroxy-[1,1′-biphen-yl]-3,5′-dicarbaldehyde) protects against airway remodeling and hyperresponsiveness via inhibiting both the activation of the mitogen-activated protein kinase and the signal transducer and activator of transcription-3 signaling pathways

Fig. 1

The ovalbumin sensitization, challenge, and drug treatment procedures. ICR mice were sensitized with ovalbumin (OVA) and aluminum hydroxide gel by intraperitonealy (i.p) and subcutaneously (s.c) injections at days 0 and 14, and an OVA (10 mg/ml) challenge was performed by aerosol for 30 min per day (q.d) from day 21 to day 28. The mice continued to be exposed to inhaled OVA (10 mg/ml) for 30 min every other day (q.o.d) from day 29 to day 84. The control mice were sensitized and challenged only with saline. ZDHXB-101 or a vehicle (CMC-Na) was given by intragastric administration (i.g) 30 min before each OVA challenge from day 21 to day 84

Back to article page